All News

The FDA has initiated approval of leucovorin calcium tablets for children with cerebral folate deficiency, which can manifest with autistic features. What is it?

New data will be shared from the PATHFINDER 2 study in asymptomatic patients and the SYMPLIFY study in patients experiencing symptoms.

Your daily dose of the clinical news you may have missed.

PODCAST: Family physician Ada Stewart, MD, shares practical strategies for cervical cancer screening and patient communication.

FDA grants Fast Track designation to etalanetug, a promising tau-targeting antibody for Alzheimer disease that could expand treatment options for the neurodegenerative disease.

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.

The administration has initiated a nationwide public service campaign about the potential risks as professional societies quickly disputed the claims.

Your daily dose of the clinical news you may have missed.

Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.

Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.

Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.

The new study, based in China, will validate urine-based genetic methylation testing which concentrates trace amounts of HPV DNA by more than 10,000 times.

FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.

The ACIP on September 19 narrowly voted against requiring a prescription to get the shot but urged more detailed discussion of vaccine risks during shared decision making conversations.

Your daily dose of the clinical news you may have missed.

Explore essential insights on cervical cancer screening, patient engagement, and innovative self-collection methods this Gynecologic Cancer Awareness Month.

If approved, the nonhormonal drug could offer an important new option for postmenopausal women seeking alternatives to hormone therapy.

Incyte announced the agency's decision, which was based on findings of significant reduction in atopic dermatitis signs and symptoms during the TRuE-AD3 clinical trial.